nodes	percent_of_prediction	percent_of_DWPC	metapath
Propiomazine—DRD4—G alpha (i) signalling events—CXCL11—nasal cavity cancer	0.0347	0.0347	CbGpPWpGaD
Propiomazine—CHRM4—G alpha (i) signalling events—CXCL11—nasal cavity cancer	0.0342	0.0342	CbGpPWpGaD
Propiomazine—DRD4—Class A/1 (Rhodopsin-like receptors)—CXCL11—nasal cavity cancer	0.0276	0.0276	CbGpPWpGaD
Propiomazine—CHRM4—Class A/1 (Rhodopsin-like receptors)—CXCL11—nasal cavity cancer	0.0272	0.0272	CbGpPWpGaD
Propiomazine—CHRM5—Class A/1 (Rhodopsin-like receptors)—CXCL11—nasal cavity cancer	0.026	0.026	CbGpPWpGaD
Propiomazine—DRD1—Class A/1 (Rhodopsin-like receptors)—CXCL11—nasal cavity cancer	0.0248	0.0248	CbGpPWpGaD
Propiomazine—ADRA1D—Class A/1 (Rhodopsin-like receptors)—CXCL11—nasal cavity cancer	0.0245	0.0245	CbGpPWpGaD
Propiomazine—DRD2—G alpha (i) signalling events—CXCL11—nasal cavity cancer	0.0236	0.0236	CbGpPWpGaD
Propiomazine—CHRM2—G alpha (i) signalling events—CXCL11—nasal cavity cancer	0.0228	0.0228	CbGpPWpGaD
Propiomazine—HTR2C—Class A/1 (Rhodopsin-like receptors)—CXCL11—nasal cavity cancer	0.0212	0.0212	CbGpPWpGaD
Propiomazine—DRD4—GPCR ligand binding—CXCL11—nasal cavity cancer	0.021	0.021	CbGpPWpGaD
Propiomazine—CHRM4—GPCR ligand binding—CXCL11—nasal cavity cancer	0.0207	0.0207	CbGpPWpGaD
Propiomazine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—CXCL11—nasal cavity cancer	0.0203	0.0203	CbGpPWpGaD
Propiomazine—CHRM5—GPCR ligand binding—CXCL11—nasal cavity cancer	0.0198	0.0198	CbGpPWpGaD
Propiomazine—DRD1—GPCR ligand binding—CXCL11—nasal cavity cancer	0.0189	0.0189	CbGpPWpGaD
Propiomazine—DRD2—Class A/1 (Rhodopsin-like receptors)—CXCL11—nasal cavity cancer	0.0187	0.0187	CbGpPWpGaD
Propiomazine—ADRA1D—GPCR ligand binding—CXCL11—nasal cavity cancer	0.0186	0.0186	CbGpPWpGaD
Propiomazine—HTR2A—Class A/1 (Rhodopsin-like receptors)—CXCL11—nasal cavity cancer	0.0184	0.0184	CbGpPWpGaD
Propiomazine—HRH1—Class A/1 (Rhodopsin-like receptors)—CXCL11—nasal cavity cancer	0.0184	0.0184	CbGpPWpGaD
Propiomazine—CHRM1—Class A/1 (Rhodopsin-like receptors)—CXCL11—nasal cavity cancer	0.0183	0.0183	CbGpPWpGaD
Propiomazine—CHRM3—Class A/1 (Rhodopsin-like receptors)—CXCL11—nasal cavity cancer	0.0183	0.0183	CbGpPWpGaD
Propiomazine—CHRM2—Class A/1 (Rhodopsin-like receptors)—CXCL11—nasal cavity cancer	0.0181	0.0181	CbGpPWpGaD
Propiomazine—ADRA1A—Class A/1 (Rhodopsin-like receptors)—CXCL11—nasal cavity cancer	0.0181	0.0181	CbGpPWpGaD
Propiomazine—HTR2C—GPCR ligand binding—CXCL11—nasal cavity cancer	0.0162	0.0162	CbGpPWpGaD
Propiomazine—ADRA1B—GPCR ligand binding—CXCL11—nasal cavity cancer	0.0155	0.0155	CbGpPWpGaD
Propiomazine—DRD2—GPCR ligand binding—CXCL11—nasal cavity cancer	0.0143	0.0143	CbGpPWpGaD
Propiomazine—HTR2A—GPCR ligand binding—CXCL11—nasal cavity cancer	0.014	0.014	CbGpPWpGaD
Propiomazine—HRH1—GPCR ligand binding—CXCL11—nasal cavity cancer	0.014	0.014	CbGpPWpGaD
Propiomazine—CHRM1—GPCR ligand binding—CXCL11—nasal cavity cancer	0.014	0.014	CbGpPWpGaD
Propiomazine—CHRM3—GPCR ligand binding—CXCL11—nasal cavity cancer	0.0139	0.0139	CbGpPWpGaD
Propiomazine—CHRM2—GPCR ligand binding—CXCL11—nasal cavity cancer	0.0138	0.0138	CbGpPWpGaD
Propiomazine—ADRA1A—GPCR ligand binding—CXCL11—nasal cavity cancer	0.0137	0.0137	CbGpPWpGaD
Propiomazine—DRD4—GPCR downstream signaling—CXCL11—nasal cavity cancer	0.0119	0.0119	CbGpPWpGaD
Propiomazine—CHRM4—GPCR downstream signaling—CXCL11—nasal cavity cancer	0.0117	0.0117	CbGpPWpGaD
Propiomazine—CHRM5—GPCR downstream signaling—CXCL11—nasal cavity cancer	0.0112	0.0112	CbGpPWpGaD
Propiomazine—DRD4—Signaling by GPCR—CXCL11—nasal cavity cancer	0.0108	0.0108	CbGpPWpGaD
Propiomazine—DRD1—GPCR downstream signaling—CXCL11—nasal cavity cancer	0.0107	0.0107	CbGpPWpGaD
Propiomazine—CHRM4—Signaling by GPCR—CXCL11—nasal cavity cancer	0.0106	0.0106	CbGpPWpGaD
Propiomazine—ADRA1D—GPCR downstream signaling—CXCL11—nasal cavity cancer	0.0105	0.0105	CbGpPWpGaD
Propiomazine—CHRM5—Signaling by GPCR—CXCL11—nasal cavity cancer	0.0102	0.0102	CbGpPWpGaD
Propiomazine—DRD1—Signaling by GPCR—CXCL11—nasal cavity cancer	0.0097	0.0097	CbGpPWpGaD
Propiomazine—ADRA1D—Signaling by GPCR—CXCL11—nasal cavity cancer	0.00957	0.00957	CbGpPWpGaD
Propiomazine—HTR2C—GPCR downstream signaling—CXCL11—nasal cavity cancer	0.00914	0.00914	CbGpPWpGaD
Propiomazine—ADRA1B—GPCR downstream signaling—CXCL11—nasal cavity cancer	0.00875	0.00875	CbGpPWpGaD
Propiomazine—HTR2C—Signaling by GPCR—CXCL11—nasal cavity cancer	0.0083	0.0083	CbGpPWpGaD
Propiomazine—DRD2—GPCR downstream signaling—CXCL11—nasal cavity cancer	0.00806	0.00806	CbGpPWpGaD
Propiomazine—ADRA1B—Signaling by GPCR—CXCL11—nasal cavity cancer	0.00794	0.00794	CbGpPWpGaD
Propiomazine—HTR2A—GPCR downstream signaling—CXCL11—nasal cavity cancer	0.00793	0.00793	CbGpPWpGaD
Propiomazine—HRH1—GPCR downstream signaling—CXCL11—nasal cavity cancer	0.00792	0.00792	CbGpPWpGaD
Propiomazine—CHRM1—GPCR downstream signaling—CXCL11—nasal cavity cancer	0.00789	0.00789	CbGpPWpGaD
Propiomazine—CHRM3—GPCR downstream signaling—CXCL11—nasal cavity cancer	0.00787	0.00787	CbGpPWpGaD
Propiomazine—CHRM2—GPCR downstream signaling—CXCL11—nasal cavity cancer	0.00779	0.00779	CbGpPWpGaD
Propiomazine—ADRA1A—GPCR downstream signaling—CXCL11—nasal cavity cancer	0.00777	0.00777	CbGpPWpGaD
Propiomazine—DRD2—Signaling by GPCR—CXCL11—nasal cavity cancer	0.00732	0.00732	CbGpPWpGaD
Propiomazine—HTR2A—Signaling by GPCR—CXCL11—nasal cavity cancer	0.0072	0.0072	CbGpPWpGaD
Propiomazine—HRH1—Signaling by GPCR—CXCL11—nasal cavity cancer	0.00719	0.00719	CbGpPWpGaD
Propiomazine—CHRM1—Signaling by GPCR—CXCL11—nasal cavity cancer	0.00717	0.00717	CbGpPWpGaD
Propiomazine—CHRM3—Signaling by GPCR—CXCL11—nasal cavity cancer	0.00714	0.00714	CbGpPWpGaD
Propiomazine—CHRM2—Signaling by GPCR—CXCL11—nasal cavity cancer	0.00707	0.00707	CbGpPWpGaD
Propiomazine—ADRA1A—Signaling by GPCR—CXCL11—nasal cavity cancer	0.00705	0.00705	CbGpPWpGaD
Propiomazine—DRD4—Signaling Pathways—CXCL11—nasal cavity cancer	0.00636	0.00636	CbGpPWpGaD
Propiomazine—CHRM4—Signaling Pathways—CXCL11—nasal cavity cancer	0.00628	0.00628	CbGpPWpGaD
Propiomazine—CHRM5—Signaling Pathways—CXCL11—nasal cavity cancer	0.00601	0.00601	CbGpPWpGaD
Propiomazine—DRD1—Signaling Pathways—CXCL11—nasal cavity cancer	0.00573	0.00573	CbGpPWpGaD
Propiomazine—ADRA1D—Signaling Pathways—CXCL11—nasal cavity cancer	0.00565	0.00565	CbGpPWpGaD
Propiomazine—HTR2C—Signaling Pathways—CXCL11—nasal cavity cancer	0.0049	0.0049	CbGpPWpGaD
Propiomazine—ADRA1B—Signaling Pathways—CXCL11—nasal cavity cancer	0.00469	0.00469	CbGpPWpGaD
Propiomazine—DRD2—Signaling Pathways—CXCL11—nasal cavity cancer	0.00433	0.00433	CbGpPWpGaD
Propiomazine—HTR2A—Signaling Pathways—CXCL11—nasal cavity cancer	0.00426	0.00426	CbGpPWpGaD
Propiomazine—HRH1—Signaling Pathways—CXCL11—nasal cavity cancer	0.00425	0.00425	CbGpPWpGaD
Propiomazine—CHRM1—Signaling Pathways—CXCL11—nasal cavity cancer	0.00423	0.00423	CbGpPWpGaD
Propiomazine—CHRM3—Signaling Pathways—CXCL11—nasal cavity cancer	0.00422	0.00422	CbGpPWpGaD
Propiomazine—CHRM2—Signaling Pathways—CXCL11—nasal cavity cancer	0.00418	0.00418	CbGpPWpGaD
Propiomazine—ADRA1A—Signaling Pathways—CXCL11—nasal cavity cancer	0.00417	0.00417	CbGpPWpGaD
Propiomazine—DRD4—Signaling Pathways—FRS2—nasal cavity cancer	0.00375	0.00375	CbGpPWpGaD
Propiomazine—CHRM4—Signaling Pathways—FRS2—nasal cavity cancer	0.0037	0.0037	CbGpPWpGaD
Propiomazine—CHRM5—Signaling Pathways—FRS2—nasal cavity cancer	0.00354	0.00354	CbGpPWpGaD
Propiomazine—DRD1—Signaling Pathways—FRS2—nasal cavity cancer	0.00338	0.00338	CbGpPWpGaD
Propiomazine—ADRA1D—Signaling Pathways—FRS2—nasal cavity cancer	0.00333	0.00333	CbGpPWpGaD
Propiomazine—HTR2C—Signaling Pathways—FRS2—nasal cavity cancer	0.00289	0.00289	CbGpPWpGaD
Propiomazine—ADRA1B—Signaling Pathways—FRS2—nasal cavity cancer	0.00277	0.00277	CbGpPWpGaD
Propiomazine—DRD2—Signaling Pathways—FRS2—nasal cavity cancer	0.00255	0.00255	CbGpPWpGaD
Propiomazine—HTR2A—Signaling Pathways—FRS2—nasal cavity cancer	0.00251	0.00251	CbGpPWpGaD
Propiomazine—HRH1—Signaling Pathways—FRS2—nasal cavity cancer	0.0025	0.0025	CbGpPWpGaD
Propiomazine—CHRM1—Signaling Pathways—FRS2—nasal cavity cancer	0.0025	0.0025	CbGpPWpGaD
Propiomazine—CHRM3—Signaling Pathways—FRS2—nasal cavity cancer	0.00249	0.00249	CbGpPWpGaD
Propiomazine—CHRM2—Signaling Pathways—FRS2—nasal cavity cancer	0.00246	0.00246	CbGpPWpGaD
Propiomazine—ADRA1A—Signaling Pathways—FRS2—nasal cavity cancer	0.00246	0.00246	CbGpPWpGaD
